Sustainability Highlights

  • Board of Directors Completed 57 Hours of Training, Averaging 8.1 Hours per Member

  • Successfully Transitioned from Emerging Stock Market to TWSE Main Board Listing

  • Flagship Project APP13007 Receives U.S. FDA Approval

  • Six Global Licensing Agreements Signed for APP13007, Paving the Way for Worldwide Launch

  • 6 Academic Presentations Completed on APNT Technology and Products

  • 14 New Patents Granted for APNT Technology, Reaching a Total of 140 Patents Worldwide

Governance

Successfully Transitioned from Emerging Stock Market to TWSE Main Board Listing

Board of Directors Completed 57 hours of Training, Averaging 8.1 Hours per Member

Flagship Project APP13007 Receives U.S. FDA Approval

Society

Completed 6 Academic Presentations on APNT Technology and Products

Executing 6 Global Licensing Agreements Signed for APP13007, Paving the Way for Global Launch

New Patents Granted for APNT Technology, Reaching a Total of 140 Patents Worldwide

Economic

ESG News Highlight

Supporting Local Diversity! Formosa Pharma Sponsors Taipei Bravo PlayOne Women’s

Formosa Pharma x Chingcheng Attorney at Law – Employee Legal

Formosa Pharma Family Day – A Gathering at Wen Sun

Dialogue in the Dark! Formosa Pharma’s In-Depth Dialogue & Listening

wtLogo

Formosa Pharmaceuticals is a clinical stage biopharmaceutical company with focus in the therapeutic areas of ophthalmology, oncology, and anti-infectives.

Company

Contact

  • +886-2-2755-7659
  • 8F-6, No. 57, Fuxing N. Rd., Songshan Dist., Taipei City 105, Taiwan

Learn More

linkedin
email
187209
Copyright © 2025 Formosa Pharmaceuticals, Inc.
Website designed by creARTive
Scroll to Top